Melanoma (Skin Cancer) Trials

E1609                               Principal Investigator: Larry Schlabach, MD

                                                Co-Investigator: John McCravey, MD and Matt Graham, MD

Title: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma (IRB#: 11-069)

NCT #: NCT01274338        Phase: Phase III

Purpose:This phase III clinical trial is studying ipilimumab or high-dose interferon alfa-2b in treating patients with high-risk stage III or stage IV melanoma that has been removed by surgery.

Drugs possibly given:
Ipilimumab
Recombinant interferon alfa-2b

Please view complete information about this trial at: http://www.clinicaltrial.gov/ct2/show/NCT01274338?term=E1609&rank=1

E3611                               Principal Investigator: Larry Schlabach, MD

                                                Co-Investigator: John McCravey, MD and Matt Graham, MD

Title: A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10mg/kg Alone or in Combination with High Dose Interferon-a in Advanced Melanoma (IRB#)

NCT #: NCT01708941        Phase: Phase II

Purpose: This randomized phase II trial studies how well ipilimumab with or without high-dose recombinant interferon alpha-2b works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Recombinant interferon alfa-2b may interfere with the growth of tumor cells. It is not yet known whether ipilimumab is more effective with or without high-dose recombinant interferon alfa-2b in treating melanoma.

Drugs possibly given:
Ipilimumab
Recombinant interferon alfa-2b

Please view complete information about this trial at: http://www.clinicaltrials.gov/ct2/show/NCT01708941?term=E3611&rank=1